| Literature DB >> 28786784 |
Zhao-Yang Wang1, Zai Wang2, Zi-Da Zhen1, Kai-Hao Feng1, Jing Guo2, Na Gao1, Dong-Ying Fan1, Dai-Shu Han3, Pei-Gang Wang1, Jing An4,1.
Abstract
Recently, Zika virus (ZIKV) outbreak has been associated with a sharp increase in cases of Guillain-Barré syndrome and severe fetal abnormalities. However, the mechanism underlying the interaction of ZIKV with host cells is not yet clear. Axl, a receptor tyrosine kinase, is postulated as a receptor for ZIKV entry; however, its in vivo role during ZIKV infection and its impact on the outcome of the disease have not been fully characterized and evaluated. Moreover, there are contradictory results on its involvement in ZIKV infection. Here we utilized Axl-deficient mice (Axl-/-) and their littermates (Axl+/-) to study the in vivo role of Axl in ZIKV infection. Our results showed that both Axl+/- and Axl-/- suckling mice supported the replication of ZIKV and presented clinical manifestations. No significant difference has been found between Axl-deficient mice and their littermates in terms of the survival rate, clinical manifestations, viral load, ZIKV distribution and histopathological changes in major organs. These results therefore indicate that Axl is not an indispensable factor for ZIKV infection in mice.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28786784 PMCID: PMC5656784 DOI: 10.1099/jgv.0.000886
Source DB: PubMed Journal: J Gen Virol ISSN: 0022-1317 Impact factor: 3.891
Fig. 1.Signs of infection and the viral load in ZIKV-infected mice. (a, b) Changes of body weight (a) and survival rates (b) of suckling mice intracerebrally injected with 100 pfu ZIKV within 72 h after birth (n=12 for Axl−/− and n=9 for Axl+/−). (c) Representative photo of mice injected with ZIKV or PBS (mock) (Axl+/− and Axl−/− as indicated) at 14 days p.i. (d) Viral loads in major organs and sera of infected mice at 10 days p.i. were determined by qRT-PCR (n=3) and expressed as the copy number per microgram of total RNA or per milliliter of sera. The copy number of the virus was standardized with ZIKV RNA transcripted in vitro.
Fig. 2.HE staining of the brain, kidney and spleen from ZIKV-infected mice. Axl-deficient (Axl−/−) newborn mice and their littermates (Axl+/−) were intracerebrally injected with 100 pfu ZIKV or the same volume of PBS (mock). The brain, kidney and spleen were harvested at 10 days p.i. and processed for HE staining as indicated. Magnification: ×40 for the cerebral cortex, hippocampus and cerebellum; ×100 for the kidney and spleen; ×400 for insets in the pictures of the kidney.
Fig. 3.Immunofluorescent staining of ZIKV antigens in the cerebral cortex and hippocampus from ZIKV-infected mice. Axl-deficient (Axl−/−) newborn mice and their littermates (Axl+/−) were intracerebrally injected with 100 pfu ZIKV and the brains were harvested at 10 days p.i. and processed for immunofluorescene of ZIKV antigens (green). Uninfected mice were used as mock control. Magnification: ×100.
Fig. 4.Co-immunofluorescence of ZIKV antigens and cellular markers in the brain. Axl-deficient (Axl−/−) newborn mice and their littermates (Axl+/−) were intracerebrally injected with 100 pfu ZIKV and the brains were harvested at 10 days p.i. Anti-ZIKV was co-immunofluorescently stained with an anti-NeuN antibody as a neuron marker (a) and an anti-GFAP antibody as astrocyte and ependymal cell markers (b). Anti-ZIKV was also co-immunofluorescently stained with the anti-Axl antibody, an indicator of the Axl expression level, in the brains from Axl+/− mice (c). Scale bar: 50 µm.